The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Novavax novel coronavirus (COVID-19) vaccine in individuals 18 years of age and older. FDA notes that the Novavax COVID-19 vaccine is administered as a two-dose primary series, three weeks apart. To read the FDA announcement and summary of its issuing an EUA for the Novavax COVID-19 vaccine for persons aged 18 and older, use the link below.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted?utm_medium=email&utm_source=govdelivery